NEW YORK, Aug. 6, 2021 /PRNewswire/ -- AIkido Pharma Inc.
(Nasdaq: AIKI) ("AIkido" or the "Company") today provided and
update on the use of Machine Learning in support of its antiviral
platform with the University of Maryland
Baltimore School of Medicine. The Company
stated:
The goal for the project is the identification and optimization
of anti-viral compounds that inhibit viral replication by targeting
a protein complex that degrades RNA at the cellular level. To
support this goal, physics-based machine learning (ML) is being
applied by SilcsBio LLC to accelerate the discovery of
broad-spectrum antivirals. These efforts are targeting the
human SKI complex that is involved in the replication of RNA
viruses from which multiple drug candidates have been identified
and shown to be effective against SARS-CoV-2 as well as other
coronaviruses, including MERS-CoV, Influenza viruses and the
filoviruses Ebola and Marburg. Ongoing efforts involve further
development of those drug candidates using the SILCS
data-driven ML ligand optimization approach in conjunction
with medicinal chemistry, biophysical characterization, and cell-
and animal-based antiviral experimental evaluation. These
collaborative efforts will yield novel chemical entities to be
considered for investigational new drug (IND) status and clinical
trials leading to therapeutic agents poised to take on the next
global pandemic.
Alex MacKerell, Grollman-Glick
Professor of Pharmaceutical Sciences and CSO, SilcsBio, LLC,
stated, "SilcsBio's machine learning algorithm combines
physics-based simulations with a data-driven machine learning
approach to iteratively improve
the predictability of the ligand optimization process. In
addition, our deep graph-based deep neural network allows screening
of more than a billion compounds in a matter of days, allowing
discovery of novel compounds much quicker than traditional
approaches. Towards addressing the global Covid-19 pandemic
SilcsBio, LLC has partnered with AIkido Pharmaceuticals
by applying its proprietary technology towards the development
of novel broad-spectrum antivirals that will also be effective
towards other viruses, including Influenza, Ebola
and Marburg."
Prof. MacKerell went on to say, "The success of these drug
development efforts are based on the power of the SilcsBio
technology to unlock hidden binding hotspots on novel
antiviral drug targets, the ability to identify sites on those
targets that alter the interactions between novel interacting
antiviral proteins and the rapid development of optimal and
effective drug leads against those targets that will define
the next generation of novel antiviral agents."
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a
biotechnology Company with a diverse portfolio of small-molecule
anti-cancer therapeutics. The Company's platform consists of
patented technology from leading universities and researchers, and
we are currently in the process of developing an innovative
therapeutic drug platform through strong partnerships with world
renowned educational institutions, including The University
of Texas at Austin and University
of Maryland at Baltimore. Our diverse pipeline of
therapeutics includes therapies for pancreatic cancer and prostate
cancer. We are constantly seeking to grow our pipeline to treat
unmet medical needs in oncology. The Company is also
developing a broad-spectrum antiviral platform that may potentially
inhibit replication of multiple viruses including Influenza virus,
SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. While the Company
believes these forward-looking statements are reasonable, undue
reliance should not be placed on any such forward-looking
statements, which are based on information available to us on the
date of this release. These forward-looking statements are based
upon current estimates and assumptions and are subject to various
risks and uncertainties, including without limitation those set
forth in the Company's filings with the SEC, not limited to Risk
Factors relating to its business contained therein. Thus, actual
results could be materially different. The Company expressly
disclaims any obligation to update or alter statements whether as a
result of new information, future events or otherwise, except as
required by law.
Contact:
Investor Relations:
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com
AIkido Pharma Inc.:
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aikido-provides-update-on-use-of-machine-learning-in-drug-development-program-301350242.html
SOURCE AIkido Pharma Inc.